Overview

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) regimen in elderly treatment-naive patient with diffuse large B-cell lymphomas.

Phase:

Phase 2

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

Lenalidomide
Rituximab
Zanubrutinib